Abstracts tagged "Biologic drugs"

Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
JoAnn Ball¹, Kelsy Greenwald¹, Atul A. Deodhar² and Kevin L. Winthrop³, ¹Rheumatology, Desert Medical Advances, Palm Desert, CA, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Oregon Health and Sciences University, Portland, OR
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…
Abstract Number: 3223 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Daniel Aletaha¹, Clifton Bingham III², Yoshiya Tanaka³, Prasheen Agarwal⁴, Regina Kurrasch⁵, Paul-Peter Tak⁶ and Sharon Popik⁴, ¹Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity and is under development for rheumatoid arthritis (RA)…
Abstract Number: 1679 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry
CJ Etzel¹, Bradley S. Stolshek², Sabrina Rebello³, David Collier⁴, Alex Mutebi⁵, Sally W Wade⁶, Wendi Malley⁷, JD Greenberg⁷ and Leslie R Harrold⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²Amgen, Thousand Oaks, CA, ³Epidemiology, Corrona, LLC, Southborough, MA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Global Health Economics, Amgen, Thousand Oaks, CA, ⁶Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁷Corrona, LLC, Southborough, MA, ⁸UMass Medical School, Worcester, MA
Background/Purpose: Little is known about factors associated with persistency of TNFi use among biologic-naïve and biologic-experienced Psoriatic Arthritis (PsA) patients in routine clinical practice in…
Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Melanie Hagen¹, Camille P Figueiredo², Jayme Fogagnolo Cobra³, Judith Haschka⁴, Michaela Reiser⁵, Matthias Englbrecht⁶, Axel J. Hueber⁷, Bernhard Manger⁶, Arnd Kleyer⁸, Stephanie Finzel⁹, Hans-Peter Tony¹⁰, Stefan Kleinert¹¹, Joerg Wendler¹², Florian Schuch¹², Monika Ronneberger¹², Martin Feuchtenberger¹³, Martin Fleck¹⁴, Karin Manger¹⁵, Wolfgang Ochs¹⁶, Matthias Schmitt-Haendle¹⁷, H.-M. Lorenz¹⁸, HG Nüßlein¹⁹, R Alten²⁰, Joerg C. Henes²¹, Klaus Krüger²², Georg Schett⁷ and Juergen Rech⁷, ¹Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ³Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ⁴Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁹Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ¹⁰Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹²Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁴Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁵Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁶Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ¹⁷Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁸Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, ¹⁹University of Erlangen, Nürnberg, Germany, ²⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ²¹Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²²Praxiszentrum St. Bonifatius, München, Germany
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
Abstract Number: 2118 • 2016 ACR/ARHP Annual Meeting
Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody Repertoire
Zoltan Konthur¹, Melvin Michael Wiemkes², Thomas Häupl³, Gerd R. Burmester⁴ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann Rheum Dis.…
Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Juliana Brunelli¹, Ana Renata Schmidt¹, Adriana M E Sallum², Cláudia Goldenstein-Schainberg³, Eloisa Bonfa⁴, Clovis A Silva⁵ and Nadia E Aikawa⁶, ¹Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…
Abstract Number: 2253 • 2016 ACR/ARHP Annual Meeting
Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
Manon Belhassen¹, Christophe Hudry², Marie-Christine Woronoff³, Liliane Lamezec⁴, Najat Gouyette⁴, Marine Ginoux¹, Eric Van Ganse¹, Florence Tubach⁵ and Bruno Fautrel⁶, ¹PELyon, Pharmacoepidemiologie Lyon, France, Lyon, France, ²AP-HP Hôpital Cochin, Paris, France, ³INSERM-U-1098, DRCI-CHRU Besançon, Franche-Comté University, UBFC, Besançon France, Besançon, France, ⁴MSD France, Courbevoie, France, ⁵Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, ⁶Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Immune-mediated rheumatic disease (IMRD) including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), are severe and disabling chronic diseases in rheumatology. Biotherapies…
Abstract Number: 404 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era
Gabriella Giancane¹, Valentina Muratore², Valentina Marzetti³, Neus Quilis⁴, Belen Serrano⁵, Alessandra Alongi⁵, Adele Civino⁶, Lorenzo Quartulli⁷, Alessandro Consolaro², Alberto Martini² and Angelo Ravelli², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³IRCCS G. Gaslini, Genoa, Italy, ⁴Pediatria II Reumatologia, IRCCS G. Gaslini, Genoa, Italy, ⁵Pediatria II, IRCCS G. Gaslini, Genoa, Italy, ⁶Azienda Ospedaliera Card G Panico, Tricase, Italy, ⁷UOC Pediatria - AO "Card.G.Panico", Tricase, Italy
Background/Purpose: The introduction of biologic agents at the beginning of the 2000s has represented a major advance in the management of juvenile idiopathic arthritis (JIA).…
Abstract Number: 2440 • 2016 ACR/ARHP Annual Meeting
First Results from the Prospective German Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Jutta Richter¹, Angela Zink³, Matthias Schneider¹, Anja Weiss², Joachim Listing⁴ and Anja Strangfeld⁵, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Epidemiology Unit, German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: There is limited evidence on the safety of treatment during pregnancy and lactation. With the increasing number of new therapeutic options for inflammatory rheumatic…
Abstract Number: 526 • 2016 ACR/ARHP Annual Meeting
Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era
Brenna Brady¹, Nicole Gerlanc¹, David Collier² and Bradley S. Stolshek³, ¹Health Analytics, LLC, Columbia, MD, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Thousand Oaks, CA
Background/Purpose: In 1998, the first biologic disease modifying antirheumatic drug was approved in the United States for the treatment of RA. Since that time, biologics…
Abstract Number: 2516 • 2016 ACR/ARHP Annual Meeting
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
Carter Thorne¹, Mohammad Movahedi², Angela Cesta², Xiuying Li², Emmanouil Rampakakis³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in the effectiveness and survival of subcutaneous vs. oral methotrexate. Furthermore, concurrent methotrexate therapy has been shown to enhance…
Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José Miguel Senabre-Gallego¹, José Rosas¹, Francisca Llinares-Tello², Mariana Marco-Mingot², Ana Pons¹, Xavier Barber³, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Marisa Lorente⁴, Marina Sanchís³, Juan Molina², Mario García-Carrasco⁵ and AIRE-MB, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³CIO, Universidad Miguel Hernández, Elche, Spain, ⁴Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…
Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Francesca Ometto¹, Bernd Raffeiner^2,3, Costantino Botsios², Davide Astorri⁴, Lara Friso², Livio Bernardi⁵, Leonardo Punzi⁶ and Andrea Doria², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, ⁴Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, ⁵Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ⁶Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 2529 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Marina Machado¹, Cristiano S. Moura², Hassan Behlouli¹, Jeffrey R. Curtis³ and Sasha Bernatsky⁴, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in the USA in November 2012 for the treatment of rheumatoid arthritis (RA). As the…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].